GLAXOSMITHKLINE UK LIMITED
Company Information
- Company Number
- 04310159
- Registered Address
- 980 Great West Road, Brentford, Middlesex, TW8 9GS
- Status
- Active
- Employee Count
- 445
- Turnover
- £596,571,000
- EBITDA
- £20,807,000
Additional Details
- Website
- https://gsk.com
- Company Type
- Private limited Company
- Incorporated On
- 24 October 2001
- Nature of Business
- 46460 - Wholesale of pharmaceutical goods
- Industries
- Life Sciences And Medical Technology
- Region
- London
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 29 Jul 2025 | 38 | 31% | 63% | 6% | 2% |
| 01 Jul 2024 - 31 Dec 2024 | 31 Jan 2025 | 45 | 24% | 73% | 3% | 2% |
| 01 Jan 2024 - 30 Jun 2024 | 30 Jul 2024 | 51 | 20% | 69% | 11% | 2% |
| 01 Jan 2023 - 30 Jun 2023 | 27 Jul 2023 | 47 | 33% | 56% | 11% | 5% |
| 01 Jan 2022 - 30 Jun 2022 | 28 Jul 2022 | 53 | 22% | 72% | 6% | 4% |
| 01 Jul 2021 - 31 Dec 2021 | 28 Jan 2022 | 45 | 34% | 58% | 8% | 4% |
| 01 Jan 2021 - 30 Jun 2021 | 29 Jul 2021 | 50 | 25% | 64% | 11% | 4% |
| 01 Jan 2020 - 30 Jun 2020 | 29 Jul 2020 | 73 | 14% | 8% | 78% | 7% |
| 01 Jul 2019 - 31 Dec 2019 | 29 Jan 2020 | 72 | 13% | 3% | 84% | 3% |
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 | 78 | 7% | 5% | 88% | 7% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Qualifying contracts for this entity contain a number of different payment periods: Immediate 30 days 60 days 45 days 30 days and 5th of the following month 60 days and 5th of the following month Payments are made from date of receipt of invoice.
Were there any changes to the standard payment terms in the reporting period?
Standard 30-day terms for SMEs were introduced in place of a previous offer of 30 day terms upon application by the vendor.
Any other information about payment terms
1) Statistics Reported: Intercompany invoices and performance have been excluded from reported statistics as these are generally wholly owned group companies and would distort performance if included. 2) Payment terms for SMEs and 'Paid on Time' monitoring: Preferential payment terms of 30 days are put in place for vendors that are confirmed as SMEs (Small and Medium Enterprises). We closely monitor our KPIs on a weekly basis to ensure that vendors (including SMEs) are paid on time. Corrective actions are taken to remedy any late payment issues where these are within the entity’s control. 3) Prompt Payment Code GSK relies on our suppliers to enable us to do business, and we want our suppliers to know they can rely on us, too. To achieve this, we believe it is important for GSK to pay suppliers on time and according to agreed terms. GSK is committed to treating our suppliers fairly and is a signatory to the Prompt Payment Code. GSK’s approach to payment practices also recognises the pressures faced particularly by small business and SMEs, and so we offer preferential 30-day payment terms for suppliers confirmed as SMEs. We will continue to seek to improve our payment performance for all suppliers in line with the Prompt Payment Code and will consider how we can best achieve this, in due course.
Maximum contractual payment period agreed
60
Dispute Resolution Process
We offer our suppliers the following support and service: Enquiries and complaints can be logged through our Helpdesk support system (mail or telephone). Issues are often related to incorrect invoice submission, payment terms are not as per contract, PO details are wrong / nonexistent etc. Key performance metrics are monitored for quality of Helpdesk support. Our Supplier web pages also include details and a link to our Speak Up channels that enable concerns to be raised, including channels managed independently of GSK and the option to do so anonymously, although naturally it helps in resolving matters if we know as much as possible about the issue and complainant. We have invested in Customer Relationship Management (CRM) to ensure effective and independent supplier follow up and support to our suppliers raising issues.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
GLAXOSMITHKLINE UK LIMITED is a leading pharmaceutical company in the United Kingdom that focuses on developing and providing innovative medicines, vaccines, and consumer healthcare products. The company is committed to improving people's health and well-being while also promoting sustainability.
Their sustainability program, known as "Planet, People, and Performance", aims to reduce their environmental impact, ensure the safety and well-being of their employees, and contribute to the communities in which they operate. This includes initiatives such as reducing carbon emissions, managing waste responsibly, and promoting diversity and inclusion within the company.
GLAXOSMITHKLINE UK LIMITED offers a wide range of products and services, including prescription medicines, vaccines, over-the-counter medicines, and health-related consumer products. They are constantly innovating and investing in research and development to bring new and improved treatments to patients.
The company's key people include the CEO, Emma Walmsley, who has been leading the company since 2017. Other key executives include the President of Pharmaceuticals, Luke Miels, and the President of Consumer Healthcare, Brian McNamara.
For more information on GLAXOSMITHKLINE UK LIMITED, their products, and sustainability efforts, you can visit their website at www.gsk.com/uk. Their registered office address is 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
